Thursday, 21 February 2019

Catalyst defends $375,000 drug price after Bernie Sanders rebuke

Catalyst Pharmaceuticals Inc, targeted by U.S. Senator Bernie Sanders for its high drug prices, said on Thursday that prices of its treatment for a rare neurological disorder were "in line" with similar products in the industry.


No comments:

Post a Comment